Menopause as a Metabolic Event: What the SWAN Cohort Shows About Insulin Resistance and Fat Redistribution

If a woman's weight barely moves through her late forties and early fifties but her waistband keeps tightening, that is not a contradiction. Data from the Study of Women's Health Across the Nation (SWAN) suggest the menopause transition is a discrete metabolic event with its own timetable: visceral fat accumulates, muscle is lost, and insulin resistance worsens in a roughly two-year window around the final menstrual period, tracking with falling estradiol rather than with birthdays. The scale can stay flat while the body underneath it is being reorganized.

Key points#

• SWAN anchored its measurements to each woman's final menstrual period (FMP), which separated the hormonal event from ordinary aging.
• Fat gain roughly doubled starting about two years before the FMP while lean mass fell, so total weight often looked stable.
• Visceral (deep abdominal) fat rose sharply in the pre-FMP window and was linked to early carotid artery changes.
• Adjusting for estradiol softened the pre-FMP acceleration, consistent with a hormonal driver.
• SWAN describes populations over time; it does not tell any individual what treatment she should choose.

The trick that made the event visible#

For a long time, midlife metabolic change in women was simply filed under "aging." The problem was one of alignment. If you plot metabolic variables against chronological age across a diverse group of women, the menopause signal smears out, because women reach menopause at different ages. SWAN, a multiethnic cohort followed for more than two decades, took a different reference point. It aligned each woman's data to her own final menstrual period.

Re-centering the timeline this way changes the picture entirely. Several body-composition and metabolic measures do not drift in a straight line across midlife. They bend at the FMP: the slope steepens in the couple of years before it, then eases afterward. A curve that bends around a hormonal landmark is the fingerprint of an event, not of steady wear. That single analytic choice is what turned a vague narrative about "getting older" into a testable claim with a beginning and an end.

Weight lies; composition tells the truth#

Greendale and colleagues used SWAN to trace body composition across an eighteen-year span, from about nine years before the FMP to ten years after, published in JCI Insight in 2019. Their most useful finding is precisely the one a bathroom scale hides. The rate of fat gain roughly doubled beginning around two years before the FMP, and lean mass declined over the same stretch. Both curves flattened within about two years after the FMP.

Body weight, meanwhile, climbed in a nearly straight line across the whole period, with no dramatic step at menopause. The math explains the mismatch. Faster fat gain and simultaneous muscle loss partly cancel on the scale, so the total can look reassuringly steady while the ratio of fat to muscle shifts underneath. Think of it as two accounts moving in opposite directions: the net balance barely changes, yet the portfolio has been rebalanced toward the riskier holding. The SWAN authors also reported that the pattern differed by race and ethnicity, a reminder that a cohort average is a description of a population, not a prediction for one person.

Not just how much fat, but where#

The location of fat matters as much as the amount. The SWAN Heart Study (Samargandy, Matthews, and colleagues, Menopause 2021) measured abdominal visceral adipose tissue, the metabolically active fat wrapped around the internal organs, across the transition. Visceral fat accumulation accelerated markedly in roughly the two years before the FMP, on the order of several percent per year, with relatively little movement earlier in the transition. When the analysis accounted for estradiol, that pre-FMP acceleration was attenuated, which is what you would expect if declining estrogen is part of what drives the redistribution.

The study did not stop at describing the fat. It connected this menopause-related visceral gain to greater thickness of the internal carotid artery wall, an early structural marker of atherosclerosis, after adjusting for traditional risk factors. That is the part worth sitting with: the central fat gathering during the transition carries a vascular signal at a stage when the process is still silent and subclinical.

Insulin resistance moves with the fat#

Visceral fat and insulin resistance tend to travel as a pair. Across SWAN analyses, insulin resistance worsened over the transition in a way that age and weight gain alone did not fully explain, which again points toward the hormonal shift itself as a contributor. Related SWAN work has examined how liver fat and sex hormone binding globulin relate to insulin resistance in midlife women. This is a network involving adipose tissue, hepatic metabolism, and sex-steroid biology, not a single switch.

The practical reading is straightforward. A woman who enters perimenopause with normal glucose handling can watch it deteriorate over the transition, and it can happen with little change in the number on the scale. That is a good reason to interpret midlife metabolic markers in the context of where a woman sits relative to her final menstrual period.

What this does not settle about hormone therapy#

It is tempting to jump from "estrogen decline drives fat redistribution" straight to a conclusion about treatment. The evidence does not license that jump, and this article is educational rather than medical advice. Observational cohorts like SWAN describe what happens to populations of women over time. They do not establish that any specific intervention will produce a particular result for an individual.

On the regulatory side, in 2025 the U.S. Food and Drug Administration moved to revise the labeling of menopausal hormone therapy products, advising sponsors to remove boxed-warning references to cardiovascular disease, breast cancer, and probable dementia, while keeping the boxed warning for endometrial cancer tied to systemic estrogen-alone therapy in women with a uterus. Read plainly, that is a change to what a label legally states and how benefit and risk are framed on it. It is not an endorsement, a recommendation, or a safety all-clear, and it does not tell any individual woman whether hormone therapy fits her situation. That decision belongs to a conversation with a clinician who knows the full picture. SWAN's contribution here is mechanistic: by clarifying why the metabolic terrain shifts, it helps women and clinicians ask sharper questions.

The bottom line#

Aligning the data to the final menstrual period converts a fuzzy story about midlife weight into a specific one. Fat gain accelerates and muscle declines in the couple of years bracketing the FMP, visceral fat rises as estradiol falls and tracks with early vascular change, and insulin resistance worsens beyond what aging alone predicts, often with the scale barely moving. Treating the transition as an event with a start and a finish is what makes sensible monitoring, and honest individual conversations, possible.